{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001042743,0.0006281533,0.004174369,0.000581733,0.0001001607,0.00001161962,0.0005845389,0.0003989621,0.001128817],"category_scores_gemma":[0.0005536791,0.000411283,0.0002072585,0.001412697,0.001460882,0.0002019363,0.0001706653,0.0008929459,0.000002028726],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004106665,"about_ca_system_score_gemma":0.006163489,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00586648,"about_ca_topic_score_gemma":0.0325509,"domain_scores_codex":[0.992521,0.001698247,0.001897902,0.0009714115,0.001960248,0.0009512026],"domain_scores_gemma":[0.9952405,0.002310305,0.0006819927,0.0007908217,0.0005787491,0.000397601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6742165,0.006190035,0.0147976,0.0002924336,0.0009429751,0.0003124843,0.005838964,0.00006191218,0.0000173041,0.00003968663,0.0000232339,0.2972669],"study_design_scores_gemma":[0.9244431,0.04980676,0.00576666,0.001380152,0.0008349624,0.00001008971,0.01322425,0.0006327107,0.0003965801,0.00006225082,0.00305905,0.0003834152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817506,0.006836482,0.000270748,0.0009770663,0.0006683488,0.007989002,0.0009069059,0.00004410062,0.0005567325],"genre_scores_gemma":[0.9936927,0.003721899,0.0002045546,0.0001885561,0.00005750541,0.001646822,0.000139055,0.00006997171,0.0002789695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2968835,"threshold_uncertainty_score":0.9998339,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01792386089167593,"score_gpt":0.4126227275079166,"score_spread":0.3946988666162407,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}